Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified Wagner-Nelson method with a nonlinear elimination model.
The clearance of recombinant human granulocyte-colony stimulating factor (rhG-CSF) is known to decrease with dose increase, and to be saturable. The average clearance after intravenous administration will be lower than that after subcutaneous administration. Therefore, the apparent absolute bioavailability with subcutaneous administration calculated from the AUC ratio is expected to be an underestimate. The absorption pharmacokinetics after subcutaneous administration was examined using the results of the bioequivalency study between two rhG-CSF formulations with a dose of 2 microg/kg. The analysis was performed using a modified Wagner-Nelson method with the nonlinear elimination model. The apparent absolute bioavailability for subcutaneous administration was 56.9 and 67.5% for each formulation, and the ratio between them was approximately 120%. The true absolute bioavailability was, however, estimated to be 89.8 and 96.9%, respectively, and the ratio was approximately 108%. The absorption pattern was applied to other doses, and the predicted clearance values for subcutaneous and intravenous administrations were then similar to the values for several doses reported in the literature. The underestimation of bioavailability was around 30%, and the amplification of difference was 2.5 times, from 8 to 20%, because of the nonlinear pharmacokinetics. The neutrophil increases for each formulation were identical, despite the different bioavailabilities. The reason for this is probably that the amount eliminated through the saturable process, which might indicate the amount consumed by the G-CSF receptor, was identical for each formulation.
Hayashi
N
N
Clinical Pharmacology Section, Clinical Research & Development Division, Chugai Pharmaceutical Co., Ltd., 1-9, Kyobashi 2-Chome, Chuo-Ku, 104-8301, Tokyo, Japan.
Aso
H
H
Higashida
M
M
Kinoshita
H
H
Ohdo
S
S
Yukawa
E
E
Higuchi
S
S
D000042:Absorption; D000704:Analysis of Variance; D001682:Biological Availability; D016179:Granulocyte Colony-Stimulating Factor / Q000493:pharmacokinetics*; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008657:Metabolic Clearance Rate; D017711:Nonlinear Dynamics; D011994:Recombinant Proteins / Q000493:pharmacokinetics; D012709:Serum Albumin / Q000378:metabolism*; D013810:Therapeutic Equivalency
D011994:Recombinant Proteins; D012709:Serum Albumin; D016179:Granulocyte Colony-Stimulating Factor